Jaguar Health, Inc. (NASDAQ:JAGX)

PRESS RELEASE

published on 04/29/2024 at 14:30, 2 years 6 months ago

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
Jaguar's plant-based drug crofelemer granted Orphan Drug Designation for MVID and SBS, with proof-of-concept studies planned for 2024. Napo sponsors Elite Ped-GI Congress panel discussion on rare digestive disorders

Crofelemer Jaguar Health Orphan Drug Designation MVID SBS
BRIEF

published on 04/22/2024 at 14:50, 2 years 6 months ago

Jaguar Health's Napo Pharmaceuticals to Exhibit at ONS Congress for Cancer Supportive Care

Patient Advocacy Cancer Supportive Care Oncology Nursing Oral Mucositis Treatment Oncology Congress
BRIEF

published on 04/22/2024 at 14:50, 2 years 6 months ago

Napo Pharmaceuticals de Jaguar Health exposera au congrès de l'ONS sur les soins de soutien contre le cancer

Soins De Soutien Contre Le Cancer Soins Infirmiers En Oncologie Traitement De La Mucite Buccale Défense Des Patients Congrès D'oncologie
PRESS RELEASE

published on 04/22/2024 at 14:45, 2 years 6 months ago

Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
Jaguar to launch FDA-approved Gelclair for oral mucositis in Q3 2024.

Jaguar Health Gelclair Oral Mucositis Cancer Supportive Care ONS Congress
BRIEF

published on 04/18/2024 at 14:35, 2 years 6 months ago

Jaguar Health Strengthens its Executive Team with a New Growth Strategy Appointee

Gelclair Cancer Supportive Care Jaguar Health, Inc. Catherine Miller Collis GI Supportive Care
BRIEF

published on 04/18/2024 at 14:35, 2 years 6 months ago

Jaguar Health renforce son équipe de direction avec la nomination d'un nouveau responsable de stratégie de croissance

Gelclair Soins De Soutien Contre Le Cancer Catherine Miller Collis Jaguar Santé, Inc. Soins De Soutien Gastro-intestinaux
PRESS RELEASE

published on 04/18/2024 at 14:30, 2 years 6 months ago

Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
Catherine Miller Collis joins Jaguar Health, facilitating in-license agreement for FDA-approved Gelclair® for oral mucositis management. Collis brings 25 years of biopharmaceutical experience to Senior VP role at Jaguar. Gelclair provides pain relief for cancer patients' supportive care needs

Cancer Treatment Jaguar Health Gelclair Oral Mucositis Catherine Miller Collis
BRIEF

published on 04/16/2024 at 14:35, 2 years 6 months ago

Jaguar Health Secures Exclusive License for FDA-Approved Oral Mucositis Gel, Targets Q3 2024 Commercial Launch

FDA Approval Jaguar Health Gelclair Oral Mucositis Cancer Supportive Care
BRIEF

published on 04/16/2024 at 14:35, 2 years 6 months ago

Jaguar Health obtient une licence exclusive pour le gel contre la mucite buccale approuvé par la FDA et vise un lancement commercial au troisième trimestre 2024

Approbation De La FDA Santé Jaguar Gelclair Mucite Buccale Soins De Soutien Contre Le Cancer
PRESS RELEASE

published on 04/16/2024 at 14:30, 2 years 6 months ago

Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Jaguar Health, Inc. announces commercial launch in Q3 2024 for Gelclair® for cancer supportive care. Gelclair is an FDA-approved oral mucositis prescription product for pain management in oncology

Jaguar Health Inc. Commercial Launch Gelclair Oral Mucositis Prescription Product

Published on 11/11/2026 at 16:30, 2 hours 12 minutes ago

ShelfieTech Announces Expansion Agreement for Its Next-Generation AI Retail Intelligence Platform
Published on 11/11/2026 at 14:25, 4 hours 17 minutes ago

Route1 Announces 2026 Annual Meeting Results
Published on 11/11/2026 at 14:00, 4 hours 42 minutes ago

PPX Mining Reports Callanquitas Operating Results for the First Nine Months of 2026
Published on 11/11/2026 at 14:00, 4 hours 42 minutes ago

NuRAN Wireless Board Approves Growth Strategy to Scale Recurring Revenue from 5,000+ Contracted Towers
Published on 11/11/2026 at 13:15, 5 hours 27 minutes ago

Amarc Extends 2026 Exploration Program at the Duke District: Initiates Drilling Program at Established Porphyry Copper-Gold Targets

View all ACCESSWIRE

Published on 11/11/2026 at 18:37, 5 minutes ago

Holding(s) in Company
Published on 11/11/2026 at 18:36, 6 minutes ago

Holding(s) in Company
Published on 11/11/2026 at 18:35, 7 minutes ago

Holding(s) in Company
Published on 11/11/2026 at 18:33, 8 minutes ago

Holding(s) in Company
Published on 11/11/2026 at 18:14, 27 minutes ago

Fresenius announces intention to sell approximately 13.4 million shares in Fresenius Medical Care AG, reducing its financial investment to approximately 20 per cent

View all EQS

Published on 11/10/2026 at 18:00, 1 day ago

Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 1 day ago

Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:40, 1 day 1 hour ago

Production du 3ième trimestre 2026
Published on 11/10/2026 at 17:35, 1 day 1 hour ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 1 day 1 hour ago

CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.

View all LES ECHOS COMFI WIRE

News